Related Experiment Video

Updated: Sep 7, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K

Tivozanib: A New Hope for Treating Renal Cell Carcinoma

Indu Passi1, Koushal Billowria1, Bhupinder Kumar1

  • 1Department of Pharmaceutical Analysis, ISF College of Pharmacy, Ghal Kalan, G.T Road, Moga, Punjab, 142001, India.

Anti-Cancer Agents in Medicinal Chemistry
|June 20, 2022
PubMed
Abstract

Insights

Tivozanib is an oral medication for advanced renal cell carcinoma (RCC). This targeted therapy effectively blocks VEGFRs, showing promise in clinical trials for RCC treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Renal cell carcinoma (RCC) is a complex cancer with varied characteristics.
  • Tivozanib (Fotivda) is an oral medication approved for relapsed or refractory RCC.

Approach:

  • A comprehensive literature search was performed across major scientific databases.
  • The review focuses on renal cell carcinoma and treatments using anti-renal carcinoma drugs.

Key Points:

  • Tivozanib is a selective oral VEGFR-1, -2, and -3 tyrosine kinase inhibitor.
  • It exhibits a long half-life, allowing for consistent VEGFR blockade.
  • Common side effects include dose-related hypertension; fatigue, hoarseness, and diarrhea are not dose-related.

Conclusions:

  • Tivozanib's specificity allows for combination therapy with other low-side-effect drugs.
  • Simultaneous blockade of VEGF and mTOR pathways offers synergistic antitumor effects and prevents resistance.
  • Tivozanib is suitable for RCC treatment and warrants further multi-center clinical investigation.
Keywords:
Renal cell carcinoma (RCC)angiogenesismalignanciestivozanibtyrosine kinase inhibitor (TKI)vascular endothelial growth factor receptor (VEGFR)

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.8K
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

9.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
816
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
150
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
249
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
307